uk.finance.yahoo.com
Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease
This reports Phase 2b trial results for duvakitug showing improved remission and endoscopic response versus placebo in UC and CD—early evidence that could lead to a new treatment option if later trials confirm benefit and safety.
Adults with moderate-to-severe UC or Crohn's disease, patients considering or on advanced therapies, clinicians treating IBD, and researchers tracking new drug development.
What To Know
New detailed Phase 2b results were presented for duvakitug (TEV'574/SAR447189) from the RELIEVE UCCD study in ulcerative colitis (UC) and Crohn's disease (CD). In UC, higher clinical remission rates at week 14 were reported for both 450 mg and 900 mg doses versus placebo, with larger placebo-adjusted effects at 900 mg.
In the CD cohort, endoscopic response at week 14 was higher with the 900 mg dose versus placebo; companies plan to start a Phase 3 program in H2 2025. The article summarizes efficacy outcomes (clinical remission in UC, endoscopic response in CD) and subgroup findings by prior advanced-therapy exposure.
It does not provide detailed safety data or full study methods in the extracted text; the original conference presentation would be the primary source for full results.
If you follow IBD clinical research, watch for the forthcoming Phase 3 program and peer-reviewed/full presentation materials for safety details, durability of response, and statistical context.
These are Phase 2b results presented at a conference; the article focuses on efficacy percentages but lacks full safety and methodological details. Phase 3 trials are planned, so this is promising early-stage data but not yet practice-changing.
